BR112022024208A2 - Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões - Google Patents

Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Info

Publication number
BR112022024208A2
BR112022024208A2 BR112022024208A BR112022024208A BR112022024208A2 BR 112022024208 A2 BR112022024208 A2 BR 112022024208A2 BR 112022024208 A BR112022024208 A BR 112022024208A BR 112022024208 A BR112022024208 A BR 112022024208A BR 112022024208 A2 BR112022024208 A2 BR 112022024208A2
Authority
BR
Brazil
Prior art keywords
neurokinin
lungs
pulmonary fibrosis
treatment
receptor antagonists
Prior art date
Application number
BR112022024208A
Other languages
English (en)
Inventor
Trower Mike
Pawsey Stephen
Kerr Mary
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of BR112022024208A2 publication Critical patent/BR112022024208A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ANTAGONISTAS DO RECEPTOR DE NEUROCININA (NK)-1 PARA USO NO TRATAMENTO DE CONDIÇÕES DE FIBROSE PULMONAR PROMOVIDAS POR LESÃO MECÂNICA AOS PULMÕES. Esta invenção se refere ao novo uso de antagonistas do receptor de neurocinina-1 como um tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões. Especificamente, quando a lesão mecânica aos pulmões é induzida por ventilação mecânica ou pelo ato de tossir em um subconjunto de pacientes com condições de fibrose pulmonar que tossem. A invenção se refere adicionalmente a composições farmacêuticas que compreendem fármacos antagonistas do receptor de neurocinina-1 e a combinações para tais usos.
BR112022024208A 2020-06-02 2021-05-28 Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões BR112022024208A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033279P 2020-06-02 2020-06-02
PCT/IB2021/054686 WO2021245512A1 (en) 2020-06-02 2021-05-28 Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Publications (1)

Publication Number Publication Date
BR112022024208A2 true BR112022024208A2 (pt) 2022-12-20

Family

ID=76375368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024208A BR112022024208A2 (pt) 2020-06-02 2021-05-28 Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Country Status (11)

Country Link
US (2) US11872222B2 (pt)
EP (1) EP4157270A1 (pt)
JP (1) JP2023531863A (pt)
KR (1) KR20230018485A (pt)
CN (1) CN115697332A (pt)
AU (1) AU2021285503A1 (pt)
BR (1) BR112022024208A2 (pt)
CA (1) CA3177477A1 (pt)
IL (1) IL298589A (pt)
MX (1) MX2022014901A (pt)
WO (1) WO2021245512A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023185931A1 (zh) * 2022-03-29 2023-10-05 人福医药集团股份公司 一种p2x3抑制剂化合物及其盐、多晶型和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106142A (en) 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
ATE277905T1 (de) 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
ES2298513T3 (es) 2002-04-26 2008-05-16 Eli Lilly And Company Derivados de tiazol como antagonistas del receptor de taquicinina.
WO2004071429A2 (en) * 2003-02-06 2004-08-26 Washington University Lung inflammation treatment
EP1706116A1 (en) 2003-12-22 2006-10-04 Schering Corporation Pharmaceutical compositions
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
EP2662373A1 (en) 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHS OF AN ANTAGONIST OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
GB0808030D0 (en) * 2008-05-01 2008-06-11 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
ES2550003T5 (es) 2008-07-17 2018-08-22 Glenmark Pharmaceuticals Limited Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones
EP2464230B1 (en) 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
WO2011104581A1 (en) 2010-02-23 2011-09-01 Nokia Corporation Menu system
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
EP3140007A1 (en) * 2014-05-05 2017-03-15 Apicore US LLC Methods of making netupitant and intermediates thereof
TW201705961A (zh) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
SI3377064T1 (sl) * 2016-01-08 2019-11-29 Nerre Therapeutics Ltd Orvepitant za zdravljenje kroničnega kašlja
US20180235931A1 (en) * 2017-01-17 2018-08-23 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives

Also Published As

Publication number Publication date
MX2022014901A (es) 2023-01-18
KR20230018485A (ko) 2023-02-07
US11872222B2 (en) 2024-01-16
US20240108621A1 (en) 2024-04-04
WO2021245512A1 (en) 2021-12-09
AU2021285503A1 (en) 2022-12-08
US20210369707A1 (en) 2021-12-02
CN115697332A (zh) 2023-02-03
CA3177477A1 (en) 2021-12-09
IL298589A (en) 2023-01-01
JP2023531863A (ja) 2023-07-26
EP4157270A1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
BR112022024208A2 (pt) Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
Raupp-Barcaro et al. Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials
BR112018005163A2 (pt) terapia de combinação de cenicriviroc para o tratamento de fibrose
BR112018068532A2 (pt) combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas
BR112012032282A2 (pt) administração transdérmica de memantina
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
Herndon et al. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl) piperazine
EA202192202A1 (ru) Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
BR112018010107A8 (pt) Composição farmacêutica para o tratamento ou prevenção de nash
Salazar-Juárez et al. Chronic dosing with mirtazapine does not produce sedation in rats
BRPI0514463A (pt) antagonistas do receptor de 5-ht7
Akbas et al. Fluoxetine-induced sleep bruxism rapidly treated with once-nightly dosing of buspirone in a 6-year-old girl
Aydillo et al. Specific mutations in the PB2 protein of influenza A virus compensate for the lack of efficient interferon antagonism of the NS1 protein of bat influenza A-like viruses
MX2021003131A (es) Antagonista de prostanoide tipo d (dp).
Shuto et al. Treatment of the Psychostimulant‐sensitized animal model of schizophrenia
Dhawan et al. ANTAGONISM OF APOMORPHINE‐INDUCED PECKING IN PIGEONS
Alguacil-Ramos et al. Safety of influenza vaccines in risk groups: analysis of adverse events following immunization reported in Valencian Community from 2005 to 2011
BR112021026561A2 (pt) Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática
Phillips Methodological considerations in clinical trials for new MDR-TB treatment regimens
Thomas et al. Inhaler errors after reading the patient information leaflet in patients with asthma: Ellipta® compared with three inhaler devices
EA201990464A1 (ru) Лекарственная форма эфедрина и его производных с защитой от несанкционированного использования
BRPI0819795B8 (pt) compostos de indano fundidos e seus usos no tratamento de doenças relacionadas ao receptor nmda, bem como composição farmacêutica compreendendo os mesmos
Lu et al. Research progress on influencing factors of partner notification in HIV infection/AIDS patients.
MX2019011485A (es) Composicion farmaceutica estabilizada para la administracion de un antagonista de leucotrieno en combinacion con un antagonista de la proteina receptora de la histamina h-1.